Filing Flows › Axsome Therapeutics (AXSM) › How it makes money
How Axsome Therapeutics (AXSM) makes money
Axsome Therapeutics (AXSM) made $260M of revenue in the third quarter 2026 (Q3 2026), +52% from a year earlier. Product brought in $250M (96%); Royalty and Milestone Revenue brought in $9.7M (4%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Product | $250M | 96.2% | +16% | +47% |
| Royalty and Milestone Revenue | $9.7M | 3.8% | +382% | +706% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $260M | 100.0% |
| Income tax | $88K | 0.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $260M | +52% |
| Q2 2026 | $218M | +46% |
| Q1 2026 | $191M | +57% |
| Q4 2025 | $196M | +65% |
| Q3 2025 | $171M | +63% |
| Q2 2025 | $150M | +72% |
| Q1 2025 | $121M | +62% |
From Axsome Therapeutics' 10-Q filed Nov 2, 2026 (on EDGAR).
Questions
How does Axsome Therapeutics make money?
Axsome Therapeutics (AXSM) made $260M of revenue in the third quarter 2026 (Q3 2026), +52% from a year earlier. Product brought in $250M (96%); Royalty and Milestone Revenue brought in $9.7M (4%).
What is Axsome Therapeutics' biggest business?
Product: $250M in the third quarter 2026, 96% of revenue, +47% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.